Systemic risk factors
In order to reduce the risk of diabetic eye disease (both retinopathy and maculopathy) progressing and causing visual loss, it is important for all people with diabetes to maintain good overall health and good control over their diabetes. This is especially important for patients who already have diabetic retinopathy (DR) which is already affecting their vision, or is likely to damage it soon.
The two most important risk factors are high blood glucose (sugar) and high blood pressure.
High cholesterol and lipids also seem to be related to DR getting worse. Treatment of high cholesterol and lipids with statin medications, if available, reduces the risk of DR progressing. Maintenance of a healthy lifestyle overall will be beneficial for DR. This includes not smoking (or giving up) and getting regular exercise. People with diabetes should follow a healthy diet and avoid sugar and refined carbohydrates as much as possible.
Eye health professionals have a role in identifying patients at risk of sight loss from DR, and reinforcing messages about diabetes control and healthy living. Screening for DR and laser treatment for DR are both good opportunities for eye health professionals to get these messages across to patients.
Laser for DR and maculopathy
Laser is the mainstay of treatment for both DR and maculopathy. Once grid is complete over oedematous area (or macula in diffuse DMO) no benefit from further grid laser. Individual microaneurysms can be targeted.
Side effects and complications
Reduction in night vision and peripheral vision Initiating/worsening DMO Foveal burn (rare)
Foveal burn Paracentral scotomas for deliberately close laser shots Glossary Clinically significant macular oedema (CSMO) CSMO is when leakage from small retinal blood vessels causes macular oedema (retinal swelling) and exudates (fat deposits from the blood) which are sufficiently close to the fovea (central macula) to affect or threaten the vision.
Diabetic maculopathy
Diabetic maculopathy is part of diabetic retinopathy. Maculopathy is damage to the macula, the part of the eye responsible for central vision.
Diabetic macular oedema (DMO) Diabetic macular oedema occurs when blood vessels near to the macula leak fluid or protein onto the macula.
Diabetic retinopathy (DR)
Diabetic retinopathy occurs when changes in blood glucose levels cause changes in retinal blood vessels. In some cases the vessels leak fluid into the macula part of the retina which swells up (DMO). In other cases, abnormal blood vessels will grow on the surface of the retina.
Peripheral retinal photocoagulation (PRP)
Cauterisation of the peripheral retina using laser, with a minimum of 2,000 effective burns.
Proliferative diabetic retinopathy
This is the advanced stage of diabetic retinopathy. New blood vessels grow along the inside surface of the retina and into the vitreous gel, the fluid that fills the eye. These vessels are fragile and more likely to leak and bleed. Scar tissue is formed and can contract and cause retinal detachment (the pulling away of the retina from underlying tissue) -which results in blindness.
The Early Treatment in Diabetic Retinopathy Study (ETDRS)
The Early Treatment in Diabetic Retinopathy study (ETDRS) has produced over 20 publications. 
When to do laser
In patients with obvious new vessels at the disc (NVD) or elsewhere in the fundus (NVE), or if there is some vitreous haemorrhage associated with new vessels, it is a straightforward decision: treat them with PRP. (These are called 'high-risk characteristics' because there is a high risk of visual loss in the ensuing years.) There are also benefits to treating patients with less advanced DR. The Early Treatment in Diabetic Retinopathy Study (ETDRS) showed that PRP treatment can prevent these patients from progressing to the high-risk state. In a resource-poor setting where follow-up of patients may be haphazard, or patients are unable to attend for regular appointments, treating patients with less severe disease will prevent them getting worse. The threshold which ETDRS has established for laser has become known as the 4-2-1 rule (see panel below) and equates to severe pre-proliferative DR. Patients with this level of DR and above should be treated.
Preventing sight loss from proliferative diabetic retinopathy
Continues overleaf ➤
The 4-2-1 rule is:
• 4 quadrants of the fundus with dense retinal haemorrhages and microaneurysms; or • 2 quadrants with venous beading; or • 1 quadrant with intra-retinal microvascular abnormalities (IRMA).
These are all signs of retinal ischaemia, which is the stimulus for eventual new vessels -leading to tractional retinal detachment, vitreous haemorrhage and visual loss.
When are haemorrhages and micro-aneurysms dense? The ETDRS study referred to standard photographs (Figure 1 ), if these are not available a rule of thumb is 5 or more haemorrhages and micro-aneurysms in a 1 mm wide slit, wherever in the quadrant you place the slit with a 90D lens.
Venous beading is clear dilation of retinal venules with accompanying constriction so it looks like a string of sausages.
IRMAs are abnormal branching, or network of vessels within the retina. ETDRS used standard photographs to define the size of IRMA that was significant. In a low-or middleincome country setting, with unreliable follow up, any definite IRMA warrants laser treatment.
Cotton wool spots are also a sign of retinal ischaemia and tend to occur in the border between well-perfused and poorly perfused retina. Although not part of the threshold, cotton wool spots are important in gaining an assessment of retinal ischaemia particularly in the absence of fluorescein angiography. They can push the clinician towards laser treatment.
Remember, these signs tend to occur together, so where there are cotton wool spots or dense haemorrhages or micro-aneurysms, look closely for IRMA or venous beading.
The 4-2-1 rule 
